Cervical intraepithelial neoplasia

Nutcracker Therapeutics Reports Strong Anti-Tumor Responses of Lead mRNA Immunotherapy in Preclinical Data Presented at SITC Annual Meeting 2022

Retrieved on: 
Friday, November 11, 2022
Research, Genetics, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, Woman, Animal, Society, Food, NK, Cervical intraepithelial neoplasia, RNA, HPV, RNA transfection, Therapy, Immunotherapy, Investigational New Drug, Cervical cancer, Technology, Criticism of the Food and Drug Administration, Nutcracker, Immunosuppression, Infection, HPV16, Society for Immunotherapy of Cancer, Tumor microenvironment, Head, CIN, B cell, Primate, Neoplasm, Vaccine, Birth control, Pharmaceutical industry

Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting.

Key Points: 
  • Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting.
  • NTX-250 is being developed for tumors driven by HPV16, which includes cervical cancer and its precursor, cervical intraepithelial neoplasia (CIN).
  • Its been our long-held belief that the RNA drug class presents a unique opportunity to create safe and effective immunotherapies.
  • The preclinical data we presented today is compelling in this regard, and shows that NTX-250 is able to induce a strong immune response and completely regress tumors in a murine model.

Global Gynecology Partnering Deal Trends, Players and Financials Report/Directory 2010-2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 6, 2022
General Health, Other Professional Services, Professional Services, Health, Pelvic inflammatory disease, Chapter Six, Menopause, Technology, Research, HPV, Premenstrual syndrome, Finance, Players, Vaginitis, Chapter One, SEC, Orientation, CIN, Chapter Two, Chapter Three, Chapter Five, Directory, Cervical intraepithelial neoplasia, Hyperlink, Chapter Four, Adenomyosis, Primary ovarian insufficiency, Polycystic ovary syndrome, Polycystic disease, Review, Contract, Video game, Birth control, Risk management, Sales, Endometriosis, Prolapse, Infertility, Dysmenorrhea, Amenorrhea, Gynaecology

The "Global Gynecology Partnering 2010-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Gynecology Partnering 2010-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Gynecology Partnering 2010-2022 report provides comprehensive access to available deals and contract documents for over 490 gynecology deals.
  • The report takes readers through the comprehensive Gynecology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gynecology deals.
  • Global Gynecology Partnering 2010 to 2022 includes:
    In Global Gynecology Partnering 2010 to 2022, available deals and contracts are listed by:

2021 Worldwide Gynecology Partnering Deals Report - Featuring Osivax, Fannin and DySIS Medical Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 23, 2021
Medical Devices, Health, Menopause, Finance, Players, Technology, Polycystic ovary syndrome, Premenstrual syndrome, Primary ovarian insufficiency, Polycystic disease, Vaginitis, Collection, Adenomyosis, HPV, CIN, Biotechnology, Cervical intraepithelial neoplasia, Pelvic inflammatory disease, Contract, Video game, Birth control, Prolapse, Endometriosis, Infertility, Gynaecology, Dysmenorrhea, Amenorrhea

The "Global Gynecology Partnering 2010-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Gynecology Partnering 2010-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • Global Gynecology Partnering 2010-2021: Deal trends, players and financials provides the full collection of Gynecology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.
  • Global Gynecology Partnering 2010 to 2021 is intended to provide the reader with an in-depth understanding and access to Gynecology trends and structure of deals entered into by leading companies worldwide.
  • In Global Gynecology Partnering 2010 to 2021, available deals and contracts are listed by:

Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review H2, 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021
Health, Clinical trials, Health, Infectious causes of cancer, Clinical medicine, Gynaecological cancer, Papillomavirus, Vaccines, Intraepithelial neoplasia, Lesion, Cervical intraepithelial neoplasia, Cin, Clinical trial, HspE7

The "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" provides an overview of the Cervical Intraepithelial Neoplasia (CIN) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Cervical Intraepithelial Neoplasia (CIN).
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
    Facilitates clinical trial assessment of the indication on a global, regional and country level
    Clinical Trials by G7 Countries: Proportion of Cervical Intraepithelial Neoplasia (CIN) to Women's Health Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Cervical Intraepithelial Neoplasia (CIN) to Women's Health Clinical Trials

United States Cervical Dysplasia Market and Competitive Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 13, 2021
Health, Women, Oncology, Consumer, Infectious causes of cancer, Cervical intraepithelial neoplasia, Clinical medicine, Health

The "US Cervical Dysplasia Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Cervical Dysplasia Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • US Cervical Dysplasia Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Cervical Dysplasia pipeline products, Cervical Dysplasia epidemiology, Cervical Dysplasia market valuations and forecast, Cervical Dysplasia drugs sales and competitive landscape in the US.
  • Cervical Dysplasia pipeline: Find out the products in clinical trials for the treatment of Cervical Dysplasia by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Cervical Dysplasia drugs: Identify key products marketed and prescribed for Cervical Dysplasia in the US, including trade name, molecule name, and company
    Cervical Dysplasia market valuations: Find out the market size for Cervical Dysplasia drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Cervical Dysplasia drugs market share: Find out the market shares for key Cervical Dysplasia drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Cervical Dysplasia products

El Paso-Based Providers Launch Mountain Star Clinically Integrated Network

Retrieved on: 
Thursday, May 13, 2021
General Health, Hospitals, Health, Practice Management, Managed care, Cervical intraepithelial neoplasia

b'A prestigious group of El Paso-based physicians today announced the launch of Mountain Star Clinically Integrated Network (\xe2\x80\x9cMountain Star CIN\xe2\x80\x9d or \xe2\x80\x9cthe CIN\xe2\x80\x9d), which was created to improve patient health outcomes through enhanced care coordination between providers.\nThrough Mountain Star CIN, which is managed by CareAllies , patients will receive extensively tailored care plans by a comprehensive network of providers who will collaborate to improve health outcomes.

Key Points: 
  • b'A prestigious group of El Paso-based physicians today announced the launch of Mountain Star Clinically Integrated Network (\xe2\x80\x9cMountain Star CIN\xe2\x80\x9d or \xe2\x80\x9cthe CIN\xe2\x80\x9d), which was created to improve patient health outcomes through enhanced care coordination between providers.\nThrough Mountain Star CIN, which is managed by CareAllies , patients will receive extensively tailored care plans by a comprehensive network of providers who will collaborate to improve health outcomes.
  • Mountain Star CIN is the latest step we are taking to achieve these goals for El Paso.\xe2\x80\x9d\nIn addition to providing greater access to data, Mountain Star CIN will also support local providers as they move into alternative payment models, such as pay-for-quality or shared savings.
  • Mountain Star CIN is setting up providers for long term success by enabling providers to select which health plans they will participate in, while still accessing resources to improve patient outcomes.\nThe new CIN will also support providers with:\nAn expanded network of providers, including specialists, to ensure high-quality outcomes\n\xe2\x80\x9cCost and health outcomes are the key concerns for all patients right now,\xe2\x80\x9d said Dr. Hector Lopez, Program Committee Member at Mountain Star.
  • Additionally, Mountain Star\xe2\x80\x99s providers communicate to ensure that a team of connected providers have a full picture of the patient\xe2\x80\x99s health.

Global Cervical Dysplasia Market (2021 to 2028) - Share, Size, Trends and Industry Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 6, 2021
General Health, Health, Oncology, Infectious causes of cancer, Cancer, Gynaecological cancer, Medical specialties, Clinical medicine, Histopathology, Oncology, Cervical cancer, Cervical intraepithelial neoplasia, Dysplasia

b'The "Cervical Dysplasia Market Share, Size, Trends, Industry Analysis Report, By Type; By End-Use, By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global cervical dysplasia market size is expected to reach USD 936.4 million by 2028 according to a new study.

Key Points: 
  • b'The "Cervical Dysplasia Market Share, Size, Trends, Industry Analysis Report, By Type; By End-Use, By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global cervical dysplasia market size is expected to reach USD 936.4 million by 2028 according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.\nThe rising prevalence of cervical cancer and awareness regarding its early diagnosis is the key cervical dysplasia industry impacting factors.
  • National Cervical Cancer Coalition under government control was responsible to highlight issues related to disease and the importance of early diagnosis.
  • These government-supported initiatives are bound to increase awareness regarding disease screening and are anticipated to boost the market growth for cervical dysplasia.\n'

Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection

Retrieved on: 
Thursday, March 18, 2021
Cancer, Infectious causes of cancer, Clinical medicine, Papillomavirus, Medicine, Gynaecological cancer, Vaccines, Sexually transmitted diseases and infections, Human papillomavirus infection, Cervical intraepithelial neoplasia, Cervical cancer, Immunotherapy

HPV001 is a randomized, placebo-controlled Phase 1/2 clinical trial designed to evaluate the safety and preliminary efficacy of VTP-200, Vaccitechs immunotherapy for high-risk HPV infection and associated low-grade cervical intraepithelial neoplasia.

Key Points: 
  • HPV001 is a randomized, placebo-controlled Phase 1/2 clinical trial designed to evaluate the safety and preliminary efficacy of VTP-200, Vaccitechs immunotherapy for high-risk HPV infection and associated low-grade cervical intraepithelial neoplasia.
  • VTP-200 targets six early proteins from five different high-risk HPV groups and therefore covers more types of HPV than any other immunotherapy previously tested.
  • Nearly all global cases of cervical cancer are caused by HPV, said Bill Enright, Chief Executive Officer of Vaccitech.
  • A non-invasive solution to clear HPV infection and the spectrum of diseases it causes is urgently needed.

Cervical Dysplasia Market Size Worth $936.4 Million By 2028 | CAGR: 7.5%: Polaris Market Research

Retrieved on: 
Wednesday, March 17, 2021
Infectious causes of cancer, Medical specialties, Histopathology, Oncology, Cervical intraepithelial neoplasia, Branches of biology, Cancer screening, Clinical medicine, Dysplasia, Gynaecological cancer

NEW YORK, March 17, 2021 /PRNewswire/ -- The global cervical dysplasia market size is expected to reach USD 936.4 million by 2028 according to a new study conducted by Polaris Market Research.

Key Points: 
  • NEW YORK, March 17, 2021 /PRNewswire/ -- The global cervical dysplasia market size is expected to reach USD 936.4 million by 2028 according to a new study conducted by Polaris Market Research.
  • Growing awareness about cervical dysplasia and the substantial rise in cancer screening programs in developing and developed countries helping the segment to grow.
  • Based on end-user, the hospital segment dominated the cervical dysplasia market and contributed the largest revenue share.
  • Feel Free to Ask Our Industry Experts at: https://www.polarismarketresearch.com/industry-analysis/cervical-dysplas...
    Polaris Market research has segmented the cervical dysplasia market report on the basis of type, end-use, and region:
    Cervical Dysplasia, by Type Outlook (Revenue USD Million, 2016 2028)

INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia

Retrieved on: 
Wednesday, February 24, 2021
Cancer, Infectious causes of cancer, Papillomavirus, Health, Medicine, Medical software, Qiagen, Human papillomavirus infection, Cervical intraepithelial neoplasia, Inovio Pharmaceuticals, Anal dysplasia, HspE7

QIAGEN is contributing an extensive track record of developing and commercializing novel diagnostic tests," said Dr. J. Joseph Kim, INOVIO'sPresident andCEO.

Key Points: 
  • QIAGEN is contributing an extensive track record of developing and commercializing novel diagnostic tests," said Dr. J. Joseph Kim, INOVIO'sPresident andCEO.
  • QIAGEN and INOVIO in 2019 announced a collaboration to develop a companion diagnostic to guide clinical decision-making for the use of INOVIO's DNA-based immunotherapy to treat cervical dysplasia caused by HPV.
  • "We are pleased to support INOVIO by developing companion diagnostics to identify patients who would benefit from VGX-3100.
  • VGX-3100is INOVIO's DNA medicine in clinical trials for the treatment of three HPV-16/18 related disease states anal dysplasia, vulvar dysplasia, and cervical dysplasia.